Last week, Protalix BioTherapeutics Inc (AMEX: PLX) unveiled a prospectus for its first offering on AMEX, representing approximately 5% of its share capital. The move signifies the company's strategic initiative to expand its capital base and foster growth opportunities, reflecting a positive outlook for the company's future prospects.